



API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/ EDMF	DMF
1	Abacavir Sulphate	Anti-Retroviral		√°*	\checkmark
2	Agomelatine (Form I) & (Form II)	Anti-Depressant			$\sqrt{\bowtie}$
3	Amisulpride	Anti-Psychotic		\sqrt{c} , \sqrt{d}	$\sqrt{\bowtie}$
4	Apixaban	Anti-Coagulant	√*		\checkmark
5	Baclofen	Muscle Relaxant	\checkmark	√°	\checkmark
6	Bilastine (Form I) & (Form II)	Anti Histamine	√*	\sqrt{d}	$\sqrt{\bowtie}$, $\sqrt{\beta}$
7	Brimonidine Tartrate	Anti-Glaucoma	\checkmark	√°	$\sqrt{\beta}$
8	Carvedilol	Anti-Hypertensive		√°	$\sqrt{\beta}$
9	Carvedilol Phosphate	Anti-Hypertensive			\checkmark
10	Carbinoxamine Maleate	Anti Histamine	√*		\checkmark
11	Cinitapride Hydrogen Tartrate	Prokinetic and Antiemetic Agent		\sqrt{d}	\checkmark \bowtie
12	Clomiphene Citrate	Ovulatory Stimulants	√*		\checkmark
13	Dabrafenib	Anti-Neoplastic			\checkmark
14	Dapoxetine HCI	Treatment of Premature Ejaculation		\sqrt{d}	$\sqrt{\bowtie}$
15	Dapagliflozin Propanediol Monohydrate	Anti Diabetic	√*		\checkmark
16	Deferasirox	Iron Chelator	\checkmark	\sqrt{c} , \sqrt{d}	$\sqrt{\bowtie}$
17	Dolutegravir Sodium	Anti-Retroviral	√*		\checkmark
18	Edoxaban Tosylate	Anti-Coagulant	√*		\checkmark
19	Epalrestat	Aldose Reductase Inhibitor			$\sqrt{\bowtie}$
20	Eszopiclone	Hypnotic	\checkmark	\sqrt{d}	$\sqrt{\beta}$
21	Ezetimibe	Dyslipidemic Agent	√*		$\sqrt{\beta}$
22	Empagliflozin	Anti Diabetic	√*		\checkmark
23	Ferric Carboxy Maltose	Treatment of Anemia			\checkmark
24	Ferric Maltol	Iron Deficiency			\checkmark
25	Finerenone	Cardiovascular	√*		\checkmark
26	Flibanserin	Female Aphrodisiac			\checkmark
27	Glycopyrrolate	Anti Cholinergic	√ *		√
28	Hydroxychloroquine Sulfate	Anti Malaria	\checkmark	√c*	√
29	Hydroxyzine HCI	Anti Histamine	\checkmark	\sqrt{c} , \sqrt{d}	$\sqrt{\beta}$

 $\sqrt{Approved}$ || $\sqrt{*}$ Filed /U/Approval || $\sqrt{*}$ CEP Approved || $\sqrt{*}$ CEP U/Approval || $\sqrt{*}$ EDMF Approved || $\sqrt{*}$ CADIFA || $\sqrt{*}$ China DMF





API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/ EDMF	DMF
30	Hydroxyzine Pamoate	Anti Histamine	√*		√
31	Idrocilamide	Skeletal Muscle Relaxant			\checkmark
32	lloperidone	Anti-Psychotic	√ *		\checkmark
33	Iron Sorbitol Dextrin Citric Acid Complex	Hematinic			\checkmark
34	Iron Sucrose LIQ & POW	Hematinic	√ *	\sqrt{d}	\checkmark
35	Iron Polymaltose	Hematinic			\checkmark
36	Itopride HCI	Gastro Prokinetic Agent		\sqrt{d}	\checkmark
37	Ketorolac Tromethamine	NSAID and Anti- inflammatory	\checkmark	\sqrt{c} , \sqrt{d}	√ ß
38	Labetalol Hydrochloride	Anti-Hypertensive	\checkmark	√°	\checkmark
39	Lacosamide	Anti-Convulsant	√ *	√°	\checkmark
40	Lamivudine	Anti-Retroviral	√ *		\checkmark
41	Lanthanum Carbonate	Phosphate Binder	\checkmark		\checkmark
42	Levocetirizine Di HCI	Anti Histamine	\checkmark	\sqrt{c} , \sqrt{d}	$\sqrt{\beta}$
43	Levodropropizine	Anti-Tussive		√c*	\checkmark
44	Levosulpiride	Anti-Psychotic		$\sqrt{d*}$	\checkmark
45	Linezolid (Form II) & (Form III)	Anti-Bacterial	\checkmark	\sqrt{d}	$\sqrt{\bowtie}, \sqrt{\beta}$
46	Linagliptin	Anti Diabetic	√ *		\checkmark
47	Lopinavir	Anti-Retroviral			\checkmark
48	Losartan Potassium	Anti-Hypertensive	√ *	√°	\checkmark
49	Lisdexamfetamine Dimesylate	Treatment of ADHD			\checkmark
50	Mavacamten	Treatment of Heart Pain (OHCM)	√ *		$\sqrt{\bowtie}$
51	Meclizine HCI	Anti Histamine	\checkmark	√ ^c	$\sqrt{\beta}$
52	Meprobamate	Anti-Anxiety	\checkmark		\checkmark
53	Modafinil	Anti-Depressant	\checkmark	√°	\checkmark
54	Mosapride Citrate Dihydrate	Gastro Prokinetic Agent			\checkmark \bowtie

^{*} OHCM - Obstructive Hypertrophic Cardiomyopathy

 $\sqrt{Approved}$ || $\sqrt{*}$ Filed /U/Approval || $\sqrt{^c}$ CEP Approved || $\sqrt{^c*}$ CEP U/Approval || $\sqrt{^d*}$ EDMF U/Approval || $\sqrt{^\beta}$ CADIFA || $\sqrt{^\bowtie}$ China DMF

Viyash Life Sciences Private Limited and its subsidiaries respect the intellectual property rights of others. No information in this catalog (including any reference to any product or service) constitutes an offer for sale of products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions. Wherever such regulatory exemptions exist, the buyer should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

^{*} ADHD - Attention Deficit Hyperactivity Disorder





API PORTFOLIO

S. No	APIs	DRUG CATEGORY	USDMF	CEP/ EDMF	DMF
55	Olmesartan Medoxomil	Anti-Hypertensive	√*	√c*	\checkmark
56	Ondansetron HCI Dihydrate	Anti Emetic		√°	$\sqrt{\beta}$
57	Otilonium Bromide	Irritable Bowel Syndrome (IBS)	√*		$\sqrt{\beta}$
58	Phentermine HCI	Anorexic	\checkmark		$\sqrt{\beta}$
59	Pregabalin	Anti-Convulsant		√°	\checkmark
60	Prucalopride Succinate	Gastrointestinal Prokinetic	\checkmark	\sqrt{d}	$\sqrt{\bowtie}$
61	Quinaldic acid	Anti-Tubercular			\checkmark
62	Racecadotril	Anti Diarrhea		\sqrt{c} , \sqrt{d}	$\sqrt{\beta}$, $\sqrt{\bowtie}$
63	Resmetirom	Treatment of NASH			\checkmark
64	Ritonavir	Anti-Retroviral			\checkmark
65	Rivaroxaban	Anti-Coagulant	\checkmark	\sqrt{c} , \sqrt{d}	$\sqrt{\beta}$
66	Selexipag IH	Treatment of Pulmonary Hypertension			\checkmark
67	Sertraline HCI (Form-I & Form II)	Anti-Depressant	√*	√c	\checkmark
68	Sucroferric Oxyhydroxide	Treatment of Hyperphosphatemia	√*		\checkmark
69	Tamsulosin HCI	Treatment of Benign prostatic hyperplasia (BPH)			✓
70	Tapentadol HCI (Form-A)	Analgesic & Anti-Inflammatory		\sqrt{c} , \sqrt{d}	$\sqrt{\beta}$
71	Tapentadol Phosphate	Analgesic & Anti-Inflammatory		\sqrt{d}	\checkmark
72	Thalidomide	Immunomodulator		\sqrt{d}	\checkmark
73	Tenofovir Disoproxil Fumarate	Anti-Retroviral	√*		\checkmark
74	Ticagrelor	Anti-Platelet	√*	√°	\checkmark
75	Tizanidine HCI	Muscle Relaxant	\checkmark	\sqrt{c} , \sqrt{d}	$\sqrt{\bowtie}$, $\sqrt{\beta}$
76	Tofisopam	Anti-Anxiety		\sqrt{d}	\checkmark
77	Vilazodone	Anti-Depressant	√*		$\sqrt{\beta}$
78	Viloxazine HCI	Treatment of ADHD	√*		$\sqrt{\beta}$
79	Vonoprazan Fumarate	Anti-Ulcer	√ *		$\sqrt{\beta}$
80	Vortioxetine HBr	Anti-Depressant	√ *	\sqrt{d}	√ ^β
81	Xanomeline Tartrate	CNS			\checkmark

^{*} NASH - Nonalcoholic Steatohepatitis





UNDER DEVELOPMENT

S.No	APIs	DRUG CATEGORY
1	5-Fluoro Uracil	Anti-Neoplastic
2	Alectinib	Anti-Neoplastic
3	Abemaciclib	Anti-Neoplastic
4	Avapritinib	Anti-Neoplastic
5	Mirogabalin	Treatment of Neuropathic Pain
6	Mirdametinib	Treatment of Neurofibrosis (NF1)

S.No	APIs	DRUG CATEGORY
7	Perfluorohexyloctane	Treatment of Dry Eye Disease
8	Ruxolitinib Phosphate/ HCI	Treatment of Myelofibrosis
9	Sparsentan	Treatment of Kidney Disease
10	Trametinib	Anti-Neoplastic
11	Vibegron	Treatment of Overactive bladder
12	Venetoclax	Anti-Neoplastic

PIPELINE

S.No	APIs	DRUG CATEGORY
1	Ademetionine	Treatment of Liver Disorder, Osteoarthritis and Depression
2	Acoramidis	Treatment of Cardiomyopathy
3	Aceclidine	Treatment of Presbyopia (Blurry Vision)
4	Alpelisib	Anti-Neoplastic
5	Atrasentan	Treatment of Proteinuria
6	Encorafenib	Anti-Neoplastic
7	Gepotidacin	Anti-Bacterial
8	Iptacopan	Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
9	Iron dextran	Hematinic
10	Letermovir	Anti-Infective

S.No	APIs	DRUG CATEGORY
11	Neratinib	Anti-Neoplastic
12	Obicetrapib	Dyslipidemic Agent
13	Opicapone	Anti-Parkinson
14	Osimertinib	Anti-Neoplastic
15	Pitolisant	Treatment of Narcolepsy
16	Sod. Zirconium Cyclosilicate	Potassium Binder
17	Selpercatinib	Anti-Neoplastic
18	Sepiapterin	Treatment of Hyperphenylalaninemia (HPA)
19	Tranexamic acid	Anti-Fibrinolytic
20	Trospium Chloride	Anti-Muscarinic
21	Vismodegib	Anti-Neoplastic

Viyash Life Sciences Private Limited and its subsidiaries respect the intellectual property rights of others. No information in this catalog (including any reference to any product or service) constitutes an offer for sale of products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions. Wherever such regulatory exemptions exist, the buyer should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.